OnKure Therapeutics, Inc. (OKUR): restructuring charge — Reneo Pharma to cut ~20% workforce, expects $1.7M severance charges in Q1 2024

OnKure Therapeutics, Inc.

Second workforce reduction of approximately 20% to be completed by February 29, 2024.
Estimated $1.7 million in cash severance and employee termination costs in Q1 2024.
Follows prior reduction announced December 14, 2023 as part of cost-saving plan.
Actual charges may differ due to assumptions and potential additional costs.

item 2.05

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

OnKure Therapeutics, Inc. announced a restructuring with charges of approximately $1.7 million (approximately 20%).

Type: restructuring
Charge: approximately $1.7 million
Headcount: approximately 20%

Exact text from the filing

the Company expects to complete a second workforce reduction of approximately 20% on February 29, 2024 (the “Second Reduction”). In connection with the Second Reduction, the Company estimates that it will incur charges of approximately $1.7 million associated with cash severance payments and other employee termination-related costs in the first quarter of 2024.

View on SEC.gov

3 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

OnKure Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-019338

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.